Bristol-Myers Squibb announces Retirement of Brian Daniels7 May 2014 | By Bristol-Myers SquibbBristol-Myers Squibb Company announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company...
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients7 May 2014 | By Boehringer IngelheimDetails of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference...
Lundbeck receives grant from The Michael J. Fox Foundation for biological markers identification in Parkinson’s disease6 May 2014 | By H. Lundbeck A/SH. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
Lundbeck to present clinical and pre-clinical data on Brintellix® at the American Psychiatric Association 167th Annual Meeting6 May 2014 | By H. Lundbeck A/SH. Lundbeck A/S announced that clinical and pre-clinical data highlighting the company’s ongoing commitment to advancing the science and treatment of depression will be presented at the American Psychiatric Association 167th Annual Meeting...
FDA approves Teva’s SYNRIBO® (omacetaxine mepesuccinate) for injection for home administration6 May 2014 | By TevaTeva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has approved SYNRIBO® (omacetaxine mepesuccinate) for injection...
Landmark study shows once-monthly long-acting therapy INVEGA® SUSTENNA® significantly delayed time to relapse in patients with schizophrenia compared to daily oral antipsychotic6 May 2014 | By Johnson & JohnsonJanssen Pharmaceuticals, Inc., announced the results of its landmark PRIDE trial...
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues6 May 2014 | By NovartisNovartis presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR in patients with acromegaly for whom current standard of care provides inadequate disease control...
Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators6 May 2014 | By Boehringer IngelheimConnexios Life Sciences and Boehringer Ingelheim announced an exclusive global research collaboration agreement for AMPK agonists for the treatment of patients with Type 2 Diabetes...
US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia6 May 2014 | By AstraZenecaAstraZeneca announced that the US Food and Drug Administration has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia...
Bristol-Myers Squibb continues to lead the advancement of immuno-oncology with broad set of new data at 2014 American Society of Clinical Oncology Annual Meeting6 May 2014 | By Bristol-Myers Squibb CompanyBristol-Myers Squibb Company announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer and metastatic renal cell carcinoma will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology...
Merck and Endocyte announce independent DSMB recommends vintafolide PROCEED Phase 3 trial be stopped for futility following interim analysis2 May 2014 | By MerckMerck and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...
European Medicines Agency presents first report on implementation of pharmacovigilance legislation to the European Commission2 May 2014 | By The European Medicines AgencyThe European Medicines Agency has presented the European Commission with its first report on the tasks it undertook during the first year of application of the EU’s new pharmacovigilance legislation...
Increased operating profit in local currencies by 15% in the first quarter of 20141 May 2014 | By Novo Nordisk7% sales growth in local currencies driven by Levemir® and Victoza®...
New TYSABRI® analysis at AAN Annual Meeting shows improved walking speed in significant number of MS patients1 May 2014 | By Biogen IdecBiogen Idec announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis patients with confirmed improvement in walking speed...
Nova Laboratories secures FDA approval for Xaluprine1 May 2014 | By Nova LaboratoriesUK pharmaceutical firm Nova Laboratories has secured U.S Food and Drug Administration approval for its acute lymphoblastic leukaemia (ALL) product Xaluprine...
